マサチューセッツ州における白血病の臨床試験
マサチューセッツ州内の拠点で、白血病に関する28件の研究が参加者を募集しています。
マサチューセッツ州内の都市
公式研究テキスト（英語）
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
- Dana-Farber Cancer Institute, Boston
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/15更新 · NCT04996875Tools for Reducing Inequity in Acute Leukemia (TRIAL): Beta Testing
- Dana-Farber Cancer Institute, Boston
被験者募集中
18歳以上 · 全性別 · 2026/09/09更新 · NCT06907797Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)
- Research Site, Boston
被験者募集中第3相
18歳〜18歳 · 全性別 · 2026/09/08更新 · NCT07509151Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation
- Massachusetts General Hospital, Boston
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/02更新 · NCT07249346CIML NK Cells With Venetoclax for AML
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/28更新 · NCT06152809Assessing PI3K Gamma Inhibition With Azacitidine, Venetoclax and Eganelisib in Patients With Acute Myeloid Leukemia
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
被験者募集中第1相
18歳〜90歳 · 全性別 · 2026/08/26更新 · NCT07439211Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- Beth Israel Deaconess Medical Center, Boston
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/20更新 · NCT06001788Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
- University of Massachusetts, Worcester
被験者募集中第3相
18歳以上 · 全性別 · 2026/08/20更新 · NCT07007312ALL Backbone in AYAs
- Dana Farber Cancer Institute, Boston
被験者募集中第2相
18歳〜51歳 · 全性別 · 2026/08/17更新 · NCT07227584Addressing Cancer Care Equity With Social Determinants of Health Screening and Early Intervention
- Mass General Brigham Cancer Institute, Boston
被験者募集中
18歳以上 · 全性別 · 2026/07/27更新 · NCT07671209Driving Inclusivity, Validity, and Equity in Research Through Strategic Engagement (DIVERSE)
- Dana-Farber Cancer Institute, Boston
被験者募集中健康なボランティア歓迎
18歳以上 · 全性別 · 2026/07/16更新 · NCT06469307Integrated Cancer Repository for Cancer Research
- Holyoke Medical Center, Holyoke
被験者募集中観察研究健康なボランティア歓迎
19歳〜110歳 · 全性別 · 2026/06/29更新 · NCT02012699A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
- Dren Investigational Site, Boston
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/06/17更新 · NCT05475925A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation
- Boston Children's Hospital, Boston
- Dana Farber Cancer Institute, Boston
被験者募集中第1相
12歳以上 · 全性別 · 2026/06/17更新 · NCT04024761Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation
- Dana-Farber Cancer Institute, Boston
- Brigham and Women's Hospital, Boston
被験者募集中第1相
18歳以上 · 全性別 · 2026/06/17更新 · NCT06138587A Personalized Neoantigen Cancer Vaccine in Treatment Naïve, Asymptomatic Patients With IGHV Unmutated CLL.
- Dana-Farber Cancer Institute, Boston
被験者募集中第1相
18歳以上 · 全性別 · 2026/05/28更新 · NCT03219450Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
- Dana-Farber Cancer Institute, Boston
被験者募集中観察研究
全年齢 · 全性別 · 2026/05/18更新 · NCT01790152A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
- Dana-Farber Cancer Institute, Boston
被験者募集中第2/3相
18歳以上 · 全性別 · 2026/04/30更新 · NCT04256317Defining the Role of Palliative carE for Patients With Hematologic Malignancies Undergoing Adoptive CEllular Therapy
- Massachusetts General Hospital Cancer Center, Boston
被験者募集中
18歳以上 · 全性別 · 2026/04/21更新 · NCT05646576Shwachman Diamond Syndrome Registry and Study
- Boston Children's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
被験者募集中観察研究
全年齢 · 全性別 · 2026/04/06更新 · NCT06056908Revumenib in Combination With 7+3 + Midostaurin in AML
- Dana-Farber Cancer Institute, Boston
被験者募集中第1相
18歳〜75歳 · 全性別 · 2026/03/25更新 · NCT06313437A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
- Massachusetts General Hospital, Boston
- UMass Chan Medical School, Worcester
被験者募集中第1相
18歳以上 · 全性別 · 2026/03/13更新 · NCT05735184Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)
- Dana-Farber Cancer Institute, Boston
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/02/11更新 · NCT06644183A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/02/05更新 · NCT07148180Mosunetuzumab for CLL MRD Clearance
- Brigham & Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
被験者募集中第1/2相
18歳以上 · 全性別 · 2025/12/15更新 · NCT07052695SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Worcester
被験者募集中観察研究
全年齢 · 全性別 · 2025/10/28更新 · NCT03452774I Can Move With Purpose Now! A Pilot Lifestyle Intervention Study in Myeloproliferative Neoplasm Patients
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
- Massachusetts General Hospital Cancer Center, Boston
被験者募集中
18歳以上 · 全性別 · 2025/09/25更新 · NCT05842603HEME Home Transfusion Program
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
被験者募集中
18歳以上 · 全性別 · 2025/09/17更新 · NCT06487247ClinicalTrials.govより、2026/10/02時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。